Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
Perrigo Spikes After Rumors It's Withdrawing From Leerink Conference
Benzinga's Top Initiations
Wall Street Breakfast: Fed Concerns Spark Market Turmoil (Seeking Alpha)
Related IPXL
Benzinga's Top Initiations
Impax Receives FDA Approval for Generic Version of Intuniv Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

Get Benzinga's Newsletters